NO305932B1 - Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren - Google Patents

Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren

Info

Publication number
NO305932B1
NO305932B1 NO934768A NO934768A NO305932B1 NO 305932 B1 NO305932 B1 NO 305932B1 NO 934768 A NO934768 A NO 934768A NO 934768 A NO934768 A NO 934768A NO 305932 B1 NO305932 B1 NO 305932B1
Authority
NO
Norway
Prior art keywords
ethyl ester
dopa ethyl
base
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
NO934768A
Other languages
English (en)
Norwegian (no)
Other versions
NO934768D0 (no
NO934768L (no
Inventor
Isaac Milman
Daphne Atlas
Alexander Veinberg
Eldad Melamed
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of NO934768D0 publication Critical patent/NO934768D0/no
Publication of NO934768L publication Critical patent/NO934768L/no
Publication of NO305932B1 publication Critical patent/NO305932B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO934768A 1992-12-24 1993-12-22 Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren NO305932B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (3)

Publication Number Publication Date
NO934768D0 NO934768D0 (no) 1993-12-22
NO934768L NO934768L (no) 1994-06-27
NO305932B1 true NO305932B1 (no) 1999-08-23

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934768A NO305932B1 (no) 1992-12-24 1993-12-22 Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren

Country Status (21)

Country Link
US (2) US5354885A (zh)
EP (2) EP0867179B1 (zh)
JP (1) JPH07285860A (zh)
CN (1) CN1083262C (zh)
AT (2) ATE178793T1 (zh)
AU (1) AU684053B2 (zh)
CA (1) CA2112160A1 (zh)
CY (1) CY2214B1 (zh)
DE (2) DE69329400T2 (zh)
DK (2) DK0610595T3 (zh)
ES (2) ES2150294T3 (zh)
FI (1) FI107994B (zh)
GR (2) GR3030073T3 (zh)
HK (1) HK1012577A1 (zh)
HU (1) HU218906B (zh)
IL (1) IL108147A (zh)
LV (1) LV12766B (zh)
NO (1) NO305932B1 (zh)
NZ (1) NZ250541A (zh)
PT (1) PT867179E (zh)
ZA (1) ZA939573B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
WO1997017067A1 (en) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals, Inc. Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
CA2350303A1 (en) * 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Process for manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003079992A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EA017983B1 (ru) * 2006-02-17 2013-04-30 Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
PL4039093T3 (pl) 2021-02-09 2024-02-05 Biobab R&D, S.L. Sposób i zastosowanie enancjomerów 3,4-dihydroksyfenyloalaniny (DOPA) do wzmagania atrakcyjności rośliny dla owadów pożytecznych

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof

Also Published As

Publication number Publication date
LV12766B (en) 2002-03-20
DE69329400D1 (de) 2000-10-12
HK1012577A1 (en) 1999-08-06
EP0610595A3 (en) 1994-09-21
EP0610595B1 (en) 1999-04-14
IL108147A (en) 1998-09-24
HU218906B (hu) 2000-12-28
DE69329400T2 (de) 2001-01-18
FI107994B (fi) 2001-11-15
NO934768D0 (no) 1993-12-22
JPH07285860A (ja) 1995-10-31
ATE196081T1 (de) 2000-09-15
CN1094950A (zh) 1994-11-16
PT867179E (pt) 2000-12-29
GR3034867T3 (en) 2001-02-28
DE69324466D1 (de) 1999-05-20
US5525631A (en) 1996-06-11
HU9303748D0 (en) 1994-04-28
AU684053B2 (en) 1997-12-04
ATE178793T1 (de) 1999-04-15
DE69324466T2 (de) 1999-11-25
LV12766A (lv) 2001-12-20
CY2214B1 (en) 2002-11-08
FI935847A0 (fi) 1993-12-23
HUT68498A (en) 1995-06-28
EP0867179B1 (en) 2000-09-06
DK0610595T3 (da) 1999-10-25
NZ250541A (en) 1995-12-21
EP0867179A1 (en) 1998-09-30
EP0610595A2 (en) 1994-08-17
US5354885A (en) 1994-10-11
DK0867179T3 (da) 2000-11-06
AU5257793A (en) 1994-07-07
GR3030073T3 (en) 1999-07-30
ES2150294T3 (es) 2000-11-16
NO934768L (no) 1994-06-27
CA2112160A1 (en) 1994-06-25
IL108147A0 (en) 1994-04-12
CN1083262C (zh) 2002-04-24
ES2132170T3 (es) 1999-08-16
FI935847A (fi) 1994-06-25
ZA939573B (en) 1994-08-11

Similar Documents

Publication Publication Date Title
NO305932B1 (no) Farmasoeytisk akseptabel L-DOPA-etylesterbase, et farmasoeytisk preparat innneholdende base, en fremgangsmåte for fremstilling av preparatet samt L-DOPA-etylesteren
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
GR3019012T3 (en) Therapeutic compositions for intranasal administration which include ketorolac TM.
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
MY125662A (en) Pharmaceutical formulations containing darifenacin
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
EP1234586A3 (en) Hepatoselective pharmaceutical actives
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
YU6196A (sh) Transdermalna flasterska formulacija
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
GB8608893D0 (en) D-nor-7-ergoline derivatives
JPS57167922A (en) Psychotropic drug
MX9801192A (es) Nuevos peptidos opioides.
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees